# US 2012/0252060 A1 · Self-Renewing Single Human Hematopoietic Stem Cells, an Early Lymphoid Progenitor and Methods of Enriching the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252060 A1
- Document ID: US20120252060A1
- Status: Published application
- Kind: A1
- Application number: 13/500,186
- Filed: 2010-10-08
- Published: 2012-10-04
- Earliest claimed: 2009-10-09
- Inventors: John Dick; Faiyaz Notta; Sergei Doulatov; Elisa Laurenti
- Web page: https://patentgrep.com/patent/US20120252060A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention relates to human hematopoietic stem cells. Specifically the invention relations to the identification of single human hematopoietic stem cells capable of long-term multilineage engraftment and self-renewal. The invention also relates to an early lymphoid progenitor with monocytic potential, including dendritic cell potential.

## Claims

### Claim 1

A method for enriching a population of cells for human hematopoietic stem cells (HSCs) comprising:
identifying and providing the population of cells that is a source of HSCs and is to be enriched for HSCs; and
sorting cells in the population by a level of CD49f expression.

### Claim 2 (depends on 1)

The method of claim 1, further comprising dividing the cells into high, intermediate and low CD49f expression groups.

### Claim 3 (depends on 2)

The method of claim 2, further comprising selecting for a sub-population of cells comprising at least one of the intermediate and high level CD49f expression groups.

### Claim 4 (depends on 2)

The method of claim 2, further comprising selecting for a sub-population of cells comprising the high CD49f expression group.

### Claim 5 (depends on 1)

The method of claim 1, further comprising sorting the cells by the level of Rhodamine-123 staining

### Claim 6 (depends on 5)

The method of claim 5, further comprising dividing the cells into high and low Rhodamine-123 staining groups.

### Claim 7 (depends on 6)

The method of claim 6, further comprising selecting cells comprising the low Rhodamine-123 staining group.

### Claim 8

A method for enriching a population of cells for human hematopoietic stem cells (HSCs) comprising:
identifying and providing the population of cells that is a source of HSCs and is to be enriched for HSCs; and
sorting cells in the population by a level of Rhodamine-123 staining.

### Claim 9 (depends on 8)

The method of claim 8, further comprising dividing the cells into high and low Rhodamine-123 staining groups.

### Claim 10 (depends on 9)

The method of claim 9, further comprising selecting for a sub-population of cells comprising the low Rhodamine-123 staining group.

### Claim 11 (depends on 1)

The method of claim 1, further comprising sorting the cells by the level of CD49f expression.

### Claim 12 (depends on 11)

The method of claim 11, further comprising dividing the cells into high, intermediate and low CD49f expression groups.

### Claim 13 (depends on 12)

The method of claim 12, further comprising selecting for cells comprising at least one of the intermediate and high level CD49f expression groups.

### Claim 14 (depends on 13)

The method of claim 13, further comprising selecting for cells comprising the high CD49f expression group.

### Claim 15 (depends on 1)

The method of claim 1; further comprising sorting cells using at least one marker selected from the group consisting of Lin, CD34, CD38, CD90, Thy1 and CD45RA.

### Claim 16 (depends on 15)

The method of claim 15, further comprising selecting at least one fraction selected from the group consisting of Lin−, CD34+, CD38−, CD90+, Thy1+ and CD45RA−.

### Claim 17 (depends on 1)

The method of claim 1, wherein the source of the population of cells is at least one of bone marrow, umbilical cord blood, mobilized peripheral blood, spleen or fetal liver.

### Claim 18 (depends on 1)

A population of cells enriched for HSCs obtained by the method of claim 1.

### Claim at position 19

-42. (canceled)
